Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO.

According to 2-year follow-up data from the phase 3 STARGLO trial, presented during the 2025 ASCO Annual Meeting, ASCT-ineligible patients with relapsed/refractory DLBCL who received glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) sustained a clinically meaningful benefit in overall survival and progression-free survival, compared with patients who received rituxumab-GemOx.